Hidroclorotiazida Vir

Hidroclorotiazida Vir is a prescription oral medication that contains the thiazide diuretic hydrochlorothiazide as its active ingredient. It is marketed in the European Union and is supplied in tablet form, though the specific strength is not disclosed. The product belongs to the antihypertensive therapeutic class and works by promoting the excretion of sodium and water to help manage blood pressure and fluid retention in patients with hypertension or edema.

Hydrochlorothiazide, the active component of Hidroclorotiazida Vir, is commonly prescribed for conditions that benefit from reduced fluid volume and lowered vascular resistance, and it is often used as part of a broader antihypertensive regimen.

- Hypertension (high blood pressure) management. - Edema associated with congestive heart failure, liver cirrhosis, or renal disease. - Prevention of fluid accumulation after surgical procedures. - Adjunct therapy in combination with other antihypertensive agents. - Short‑term control of blood pressure spikes in certain clinical scenarios. - Management of calcium‑containing kidney stones in selected patients.

Like other thiazide diuretics, Hidroclorotiazida Vir may cause a range of adverse reactions, most of which are mild and reversible.

Common: - Increased frequency of urination, which may be noticeable especially during the first few days of therapy. - Low blood potassium (hypokalemia), potentially causing muscle cramps or weakness. - Dizziness or light‑headedness upon standing, reflecting a transient drop in blood pressure.

Serious: - Severe dehydration or electrolyte disturbance that may require medical attention. - Acute kidney injury manifested by reduced urine output or rising creatinine levels. - Allergic reactions such as rash, itching, or facial swelling that could indicate hypersensitivity.

Before initiating Hidroclorotiazida Vir, healthcare providers consider several safety factors to minimize risks and ensure appropriate use.

- Assess renal function; avoid use in patients with severe impairment. - Monitor serum electrolytes, especially potassium and sodium, during treatment. - Use caution in individuals with a history of gout, as uric acid levels may rise. - Evaluate blood glucose regularly in diabetic patients, since thiazides can increase glucose. - Consider potential interactions with other antihypertensives that may amplify hypotensive effects. - Avoid in patients with known hypersensitivity to thiazide diuretics. - Use the lowest effective dose and re‑evaluate need periodically.

Hydrochlorothiazide can affect the pharmacokinetics or pharmacodynamics of several other medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid: - Concurrent use with lithium, which can raise lithium levels and cause toxicity. - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that may blunt diuretic efficacy and impair kidney function. - Co‑administration with digoxin without dose adjustment, due to increased risk of digoxin toxicity from electrolyte shifts.

Use with caution: - ACE inhibitors or ARBs, which together may enhance potassium loss. - Antidiabetic agents, as thiazides may reduce glucose control. - Corticosteroids, which can increase sodium retention and counteract the diuretic effect.